Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin in Relapsed or Refractory Plasmablastic Lymphoma and ALK+ Large B-cell Lymphoma
NCT04676360Phase 2Terminated
- Start
- Jul 2021
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belantamab mafodotin in plasmablastic lymphoma (PBL) and ALK-positive large B-cell lymphoma. Primary endpoint: Overall Response Rate up to 2 years. Started Jul 2021; status: terminated.
02
Drugs
belantamab mafodotin
03
Conditions
plasmablastic lymphoma (PBL)ALK-positive large B-cell lymphoma
Beyond the preview
Go deeper on NCT04676360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676360.